Compare Abbott Laboratories (ABT) vs Nutrien Ltd (NTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Nutrien Ltd — how do they compare? Abbott Laboratories trades at $95.38 (market cap $166.94B), while Nutrien Ltd trades at $66.68 (market cap $31.34B). The key difference: Abbott Laboratories is far larger — about 5.3× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.37%). Which is the better fit depends on your goals.
| ABT | NTR | |
|---|---|---|
Market Cap | $166.94B | $31.34B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $83.94 |
52-Week Low | $82.57 | $53.64 |
Enterprise Value | $193.69B | $44.51B |
Dividend Yield | 2.63% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Nutrien (NTR) trades at $65.32, up 0.4% with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with Q1 2026 earnings beating estimates and revenue growth projected to $27.8B in 2026. Analyst consensus is strongly bullish with a $81.86 price target, representing 25% upside potential from current levels.
NTR presents value with attractive valuation multiples (P/E 13.14, P/S 1.12) and strong fertilizer demand fundamentals. Key risks include volatile input costs, supply chain disruptions, and debt refinancing needs. The stock offers dividend income with recent $0.55 payout, positioning it as a compelling agribusiness investment amid global food security trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
